House of Commons
As this motion is using historical data, we may not have the record of the original ordering, in which case signatories are listed alphabetically.
GLAXOSMITHKLINE AND SEROXAT
EDM #2172
Tabled 15 May 2006
2005-06 Session
That this House condemns GlaxoSmithKline (GSK) for concealing for 15 years evidence that their anti-depressant drug Seroxat increases the risk of suicide and leads to `persistently worse' depression; congratulates the US Food and Drug Administration for forcing GSK to confess that users of Seroxat `experience emergent suicidality or symptoms that might be precursors to worsening depression or suicidality' and that `these symptoms may be severe and abrupt in onset'; and regrets the likely loss of life that has resulted from repeated denials of the lethal side effects of Seroxat by GSK, the Association of the British Pharmaceutical Industry and the Medicine and Healthcare Product Regulatory Agency in spite of the vigorous campaigns to reveal the truth by Professor David Healy, hon. Members, the Seroxat Users Group and Panorama.

Signatures (40)

The first 6 Members who have signed to support the motion are the sponsors. The primary sponsor is generally the person who tabled the motion and has responsibility for it. The date shown is when the Member signed the motion.
In addition to the sponsors, the following Members have signed to support the motion.
There are no withdrawn signatures for this Motion